Wave Life Sciences二季度更新确认WVE-007肥胖症Phase 2a给药推进及WVE-006拟与FDA讨论加速批准路径

Dosing underway in
Phase 2a
multidose portion
of the INLIGHT
TM
trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m
2
) and comorbidities;
trial will also inform WVE-007's potential
in MASH, type 2 diabetes, and other cardiometabolic diseases
Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026
FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing); data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATD
CTA submission for WVE-008 for PNPLA3 liver disease (GalNAc-RNA editing) on track for 2H 2026
Well capitalized with cash, cash equivalents, and marketable securities of $490.6 million as of June 30, 2026 and expected cash runway into 3Q 2028
Investor conference call and webcast at
8:30 a.m. ET
today
CAMBRIDGE, Mass.
,
July 30, 2026
(GLOBE NEWSWIRE) --
Wave Life Sciences Ltd.
(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the second quarter ended
June 30, 2026
, and provided a business update.
“Our second quarter performance reflects disciplined execution across the pipeline,” said
Paul Bolno
, MD, MBA, President and Chief Executive Officer at
Wave Life Sciences
. “We recently initiated dosing in the Phase 2a portion of our INLIGHT trial in obesity. Our Phase 1 clinical data have already demonstrated substantial reductions of fat – particularly harmful visceral fat – without muscle loss, and with the potential for once or twice-yearly dosing. We expect the Phase 2a portion of the INLIGHT trial, in individuals with higher BMI and higher body fat, to demonstrate WVE-007's broad potential to deliver even greater fat loss and improvements in body composition, as well as benefits across additional cardiometabolic biomarkers such as liver fat. In tandem with this progress, we are working expeditiously to initiate Phase 2 trials evaluating WVE-007 in combination with incretins and as post-incretin maintenance; we believe WVE-007 has the potential to transform the current obesity treatment landscape.”
Dr. Bolno
added, “In RNA editing, our RestorAATion-2 clinical data support WVE-006’s potential to offer a new standard of care for individuals living with AATD by treating both lung and liver manifestations of the disease, and restoring dynamic response of AAT protein, with convenient, infrequent subcutaneous dosing, and without the risks associated with DNA editing. We look forward to meeting with the FDA to discuss a pathway for accelerated approval for WVE-006. Building on our clinical success in RNA editing, WVE-008, our PNPLA3 RNA editing program, has the potential to address the nine million individuals living with this genetic liver disease. It’s exciting to see the clinical translation of our RNAi and RNA editing programs, enabled by our unique and proprietary chemistry, and supported by human genetics. We expect to provide further updates on our pipeline and platform innovations at our annual investor day this fall.”
Recent Business Highlights and Expected Milestones
Obesity
WVE-007
is an investigational GalNAc-siRNA (SpiNA) designed to induce fat loss without muscle loss. With strong evidence from human genetics, silencing INHBE mRNA is a promising therapeutic strategy to treat obesity, distinct from incretin-based approaches. WVE-007 is being evaluated in the ongoing placebo-controlled INLIGHT clinical trial.
Phase 1 INLIGHT trial:
The ongoing, single dose portion is evaluating otherwise healthy individuals with less fat and lower BMI (average ~32 kg/m
2
) than Phase 2 and 3 obesity trials. Data from the INLIGHT trial have demonstrated total body fat reduction, with muscle preservation, as well as clinically meaningful reductions in visceral fat
1
and waist circumference. WVE-007 continued to be generally safe and well tolerated and data support potential for once or twice-yearly dosing. Additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026.
Phase 2a INLIGHT trial:
Dosing is underway in the Phase 2a multidose portion of the INLIGHT trial of WVE-007 in individuals with higher BMI (35-50 kg/m
2
), with and without type 2 diabetes. This portion of the INLIGHT trial is evaluating participants with greater adiposity, consistent with Phase 2 and 3 obesity trials. This portion of the trial is enrolling participants across the
U.S
. and
Europe
and includes multiple assessments over a 12-month period, including body weight, waist circumference, body composition (MRI and DEXA), liver fat (MRI-PDFF), HbA1c, and lipid levels. These data will inform further development of WVE-007 in obesity, as well as in MASH, type 2 diabetes, and other cardiometabolic diseases.
Combination with incretin and post-incretin maintenance:
Wave expects to initiate Phase 2 trials of WVE-007 in the combination and maintenance settings in the second half of 2026.
Alpha-1 antitrypsin deficiency (AATD)
WVE-006
is an investigational GalNAc-conjugated, subcutaneously delivered, RNA editing oligonucleotide (AIMer) for AATD. WVE-006 is being evaluated in the ongoing Phase 1b/2a RestorAATion-2 open-label clinical trial in individuals with AATD who have the homozygous Pi*ZZ mutation.
RestorAATion-2 trial:
The 200 mg, 400 mg, and 600 mg cohorts are fully enrolled and dosing is complete.
In
May 2026
, the company shared
clinical data
from the 200 mg (single and biweekly), 400 mg (single and monthly), and 600 mg (single dose) cohorts of the ongoing RestorAATion-2 clinical trial that demonstrated WVE-006 achieved key AATD treatment goals by recapitulating an MZ-like phenotype, including robust, dose-dependent reductions of circulating, mutant Z-AAT protein, with corresponding increases in wild-type M-AAT protein, and restoration of dynamic AAT response. Wave expects to share data from the 600 mg (monthly) multidose cohort in the second half of 2026.
Wave’s request for a meeting regarding a potential accelerated approval pathway for WVE-006 was granted by the
U.S. Food and Drug Administration
(FDA). The meeting is scheduled for the end of summer 2026.
PNPLA3 I148M liver disease
WVE-008:
Wave is building on its clinical success in RNA editing by advancing WVE-008, a GalNAc-conjugated AIMer for homozygous PNPLA3 I148M liver disease. There is a growing body of clinical evidence supporting RNA editing as a preferred therapeutic strategy over silencing.
In
May 2026
, Wave shared preclinical data supporting WVE-008 in a poster presentation at the
European Association for the Study
of the
Liver (EASL) Congress
. These data demonstrated that Wave’s PNPLA3 AIMers delivered substantial editing of the PNPLA3 I148M transcript, exceeding the ~50% threshold expected to lower risk for liver disease.
A clinical trial application (CTA) filing for WVE-008 is on track for the second half of 2026.
Other pipeline programs (HD and DMD)
Wave continues partnering discussions for WVE-003 (Huntington’s disease) and WVE-N531 (Duchenne muscular dystrophy, exon 53). With respect to WVE-N531, Wave is evaluating the evolving regulatory and commercial landscape in DMD and exploring potential partnerships in advance of filing a New Drug Application (NDA).
Emerging pipeline
Investor Day 2026:
Wave plans to host an investor day in the fall of 2026, where the company expects to share updates from its clinical and preclinical pipeline of RNA medicines.
Financial Highlights
Cash, cash equivalents, and marketable securities were
$490.6 million
as of
June 30, 2026
, compared to
$602.1 million
as of
December 31, 2025
. Wave expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into the third quarter of 2028. Potential future milestone and other payments to Wa